Loading
Latest filing published 25 Jun 2026 for ENDRA Life Sciences Inc., €374k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Only one filing by Anthony DiGiandomenico is known so far (25 June 2026): a transaction, €374k, in ENDRA Life Sciences Inc. That is too little to draw conclusions. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration